Century Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CENTURY THERAPEUTICS, INC. | |
| By: | /s/ Brent Pfeiffenberger, PharmD, MBA |
| Brent Pfeiffenberger, PharmD, MBA | |
| Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| /s/ Brent Pfeiffenberger, PharmD, MBA | Chief Executive Officer and Director (principal executive officer) | March 19, 2025 | ||
| Brent Pfeiffenberger, PharmD, MBA | ||||
| Chief Financial Officer(principal financial officer) | March 19, 2025 | |||
| /s/ Morgan Conn, PhD | | | ||
| Morgan Conn, PhD | | | ||
| | | | | |
| /s/ Douglas Carr | | Senior Vice President, Finance & Operations | | March 19, 2025 |
| Douglas Carr | | (principal accounting officer) | | |
| | | | | |
| /s/ Kimberly Blackwell, M.D. | Director | March 19, 2025 | ||
| Kimberly Blackwell, M.D. | ||||
| | | | | |
| /s/ Cynthia Butitta | Director | March 19, 2025 | ||
| Cynthia Butitta | ||||
| | | | | |
| /s/ Joseph Jimenez | Director, Chairman of the Board | March 19, 2025 | ||
| Joseph Jimenez | ||||
| | | | | |
| /s/ Alessandro Riva, M.D. | Director | March 19, 2025 | ||
| Alessandro Riva, M.D. | ||||
| | | | | |
| /s/ Carlo Rizzuto, Ph.D. | Director | March 19, 2025 | ||
| Carlo Rizzuto, Ph.D. | ||||
| | | | | |
| /s/ Timothy Walbert | | Director | | March 19, 2025 |
| Timothy Walbert | | | ||
| | | | | |
| /s/ Daphne Quimi | | Director | | March 19, 2025 |
| Daphne Quimi | | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.